Comparing a new drug plus surgery vs. surgery alone for TGCT
Part of Bones, joints & muscles, Cancer clinical trials.
This trial tests whether taking pimicotinib before surgery improves outcomes for people with diffuse tenosynovial giant cell tumor (a non-cancerous growth in joints). You would receive the study drug for a while, then have surgery, and be compared to people who have surgery right away.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of joint tumor called diffuse tenosynovial giant cell tumor (D-TGCT) that can be removed with surgery.
- Your tumor is at least 2 centimeters in size.
- You have pain or stiffness in the joint that you rate as 4 or higher on a scale of 0 to 10.
- You have not taken drugs that block CSF1 or CSF1R before.
- You are willing to fill out questionnaires about how you feel during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether taking imatinib before surgery can shrink or control high-risk gastrointestinal stromal tumors (GIST). If you qualify, you would receive imatinib as “neoadjuvant” (before the operation) and then move on to planned surgery.
This trial tests a new drug called pimicotinib for people in Japan with tenosynovial giant cell tumor (TGCT) that cannot be removed by surgery. It aims to see if the drug can help with pain and stiffness caused by the tumor.
This trial tests whether adding a new drug called CGT9486 to sunitinib (a standard cancer drug) works better than sunitinib alone for gastrointestinal stromal tumors (GISTs) that have grown or spread. You may qualify if your GIST stopped responding to or caused problems with imatinib, an earlier treatment.
This Phase 1 study tests how safe a new drug (ABSK-021) is, what side effects it causes, and how the body processes it in people with advanced solid tumors. You may be eligible if your cancer has grown despite standard treatments or if no standard treatment exists.
This trial tests whether combining two oral medications, imatinib and fampridine, before surgery can shrink GIST tumors that have a specific KIT gene mutation. The goal is to improve surgical outcomes and potentially reduce the risk of the tumor coming back.
This trial tests two drugs given before surgery to shrink tumors in people with a type of lung cancer (non-small cell) that has a specific protein called PD-L1. The goal is to see if this treatment helps remove the cancer more effectively.
Hear when a new Tenosynovial Giant Cell Tumor, Diffuse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.